COMPARISON OF TRADITIONAL OUTCOME MEASURES AND SELF-ASSESSED GOAL ACHIEVEMENT IN PATIENTS TREATED SURGICALLY FOR BENIGN PROSTATIC HYPERPLASIA

therapy followed by Rezum was the second most effective option (15.08 QALY), followed by Urolift (14.99 QALYs) as initial treatment, and, lastly, pharmacotherapy followed by UroLift (14.98 QALY). CONCLUSIONS: MITs are effective treatment options for moderate-to-severe BPH. These findings will be beneficial for clinicians and health policy makers to further define the implementation of MITs in treatment for BPH.